Physician

Vera Maranci, M.D.

According to 2025 Medicare claims, Vera Maranci, M.D. (NPI: 1922207588) practices hematology/oncology in the Detroit-Dearborn-Livonia, MI market, with the plurality of this provider's patient population coming from Wayne, MI. This provider's primary affiliated billing organization is CANCER & HEMATOLOGY CENTERS OF WESTERN MI, P.C. (NPI: 1528018389; TIN: 382777354) and primary practice location at 48066-5821.

Maranci's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 504 traditional Medicare patients, billed 82,328 HCPCS/CPT codes, and received $1,498,166 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 1,274 prescription claims across 272 beneficiaries totaling $3,256,972 in drug costs, led by Revlimid (Lenalidomide). DME data shows 31 claims. Open Payments data shows 19 records totaling $358. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $429,101 to $1,498,166. Similarly, Part D prescription costs have moved sharply higher in recent years, from $365,130 to $3,256,972. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	499	44,062	$429,101
2016	491	42,106	$377,324
2017	544	83,625	$492,476
2018	682	75,117	$404,655
2019	578	72,504	$723,572
2020	507	70,821	$949,151
2021	551	79,555	$746,323
2022	589	76,466	$927,723
2023	551	79,331	$1,334,575
2024	504	82,328	$1,498,166

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	106	653	$365,130
2016	118	708	$275,913
2017	147	896	$686,725
2018	182	968	$714,077
2019	183	926	$777,862
2020	189	1,097	$1,112,378
2021	206	977	$1,618,622
2022	210	953	$2,029,742
2023	242	1,197	$2,305,143
2024	272	1,274	$3,256,972

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	71	$6,929
2016	N/R	25	$2,427
2017	N/R	74	$16,353
2018	N/R	78	$9,698
2019	N/R	74	$6,867
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	31	$936

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	131	159	$137
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	250	582	$90
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	126	364	$63
36415	Insertion of needle into vein for collection of blood sample	269	738	$8
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	266	776	$7

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	42	1,106	$720,525
Imbruvica	Ibrutinib	23	644	$369,843
Pomalyst	Pomalidomide	11	308	$248,569
Ibrance	Palbociclib	15	420	$232,194
Eliquis	Apixaban	259	12,314	$229,513

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	13	$597
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	18	$339

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	19	$358	Gilead Sciences, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Vera Maranci, M.D.?

Tedicare shows public-source Medicare data for Vera Maranci, M.D. (NPI 1922207588), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Vera Maranci, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Vera Maranci, M.D.?

Vera Maranci, M.D. is linked to CANCER & HEMATOLOGY CENTERS OF WESTERN MI, P.C. (billing NPI 1528018389) in the available physician profile data.

Does Vera Maranci, M.D. have Open Payments data?

Vera Maranci, M.D. has 19 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.